In Reply We appreciate the interest in our article and thank JAMA Surgery for the opportunity to reply to the letters to the editor.¹ Shi et al advised that combining patients without postoperative pancreatic fistula (POPF) and with biochemical leakage may have biased the analysis regarding long-term survival in patients receiving neoadjuvant therapy (NAT). While biochemical leakage may reflect a more preserved gland function, which has been associated with better survival in upfront resected pancreatic cancer,² a preliminary analysis had shown no significant differences between biochemical leakage and no pancreatic fistula in patients with NAT.

中文翻译：

---

胰腺瘘在新辅助治疗胰腺癌切除患者中的预后价值。

回覆我们感谢您对本文的关注，并感谢JAMA Surgery借此机会回信给编辑。¹ Shi等人建议，合并无术后胰瘘（POPF）和生化渗漏的患者，可能会对接受新辅助疗法（NAT）的患者的长期生存产生偏见。虽然生化渗漏可能反映了更保留的腺体功能，这与前期切除的胰腺癌的较好生存率相关，²初步分析显示，NAT患者的生化渗漏和无胰腺瘘之间无显着差异。